Can I Take Creatine with Rapamycin (Sirolimus)?

How Sirolimus Works and Why the Kidneys Matter

Sirolimus (brand name Rapamune) is a macrolide that binds FKBP12 and inhibits mTORC1, the master regulator of cell growth and protein synthesis. The FDA approved it in 1999 for prevention of renal allograft rejection, and it is now used off-label by longevity-focused clinicians at doses ranging from 1 mg to 8 mg once weekly [1].

The kidney connection is direct. Sirolimus can cause proteinuria, impair glomerular filtration, and, especially when combined with calcineurin inhibitors like tacrolimus, produce clinically significant nephrotoxicity [2]. Even in off-label longevity protocols where sirolimus is used without calcineurin inhibitors, prescribing physicians order a comprehensive metabolic panel (CMP) at baseline, then again at 4 to 6 weeks, and every 3 to 6 months thereafter.

Sirolimus Is a CYP3A4 Substrate

Sirolimus is metabolized almost entirely by hepatic CYP3A4 and is a substrate of P-glycoprotein. Strong CYP3A4 inhibitors (ketoconazole, clarithromycin) can raise trough sirolimus levels three- to five-fold, while inducers (rifampin) can drop them by 90% [3]. This makes sirolimus one of the more drug-sensitive immunosuppressants in clinical practice.

Creatine does not inhibit or induce CYP3A4 or P-glycoprotein. No pharmacokinetic pathway connects them. The interaction risk here lives entirely in the lab report, not in the metabolic machinery.

Why Renal Biomarkers Get Complicated

Serum creatinine is a waste product of phosphocreatine breakdown in muscle. When you add exogenous creatine monohydrate, total body phosphocreatine stores expand, and the daily creatinine output rises accordingly. A systematic review published in Nephrology Dialysis Transplantation confirmed that healthy adults supplementing with 20 g/day creatine for 5 days showed mean serum creatinine increases of up to 0.23 mg/dL, with smaller but persistent rises of 0.08 to 0.12 mg/dL on maintenance doses of 3 to 5 g/day [4].

That 0.1 to 0.3 mg/dL shift is harmless in a healthy person. In a transplant patient or a longevity patient whose physician is tracking kidney function against a tight reference range, it can look like early graft dysfunction or drug-related nephrotoxicity, triggering unnecessary dose reductions, invasive workup, or alarm.

The Pharmacodynamic Overlap: mTOR, Muscle, and Creatine

This is where the biology becomes genuinely interesting rather than just a lab artifact.

Sirolimus Suppresses Muscle Protein Synthesis

MTORC1 phosphorylates S6K1 and 4E-BP1, which drive ribosomal translation of new muscle protein. Sirolimus blocks this pathway. A randomized trial by Drummond et al. In the American Journal of Physiology showed that oral rapamycin given before a bout of resistance exercise suppressed mixed muscle protein synthesis by roughly 40% compared to placebo, measured by stable isotope tracer methodology [5]. This is a meaningful blunting of the anabolic signal from training.

For transplant patients, this is rarely a primary concern. For the growing cohort of healthy adults in their 40s through 70s who are taking low-dose weekly sirolimus for longevity, muscle preservation is very much on the agenda.

What Creatine Does to Muscle Independently of mTOR

Creatine monohydrate raises intramuscular phosphocreatine, speeds ATP regeneration during high-intensity effort, and supports satellite cell signaling through mechanisms that are at least partially independent of mTORC1. A Cochrane-adjacent meta-analysis in the Journal of Strength and Conditioning Research (177 studies, N over 3,200) found that creatine supplementation added 1.37 kg of lean mass and improved upper-body strength by 6.8% relative to placebo across diverse populations [6]. The mechanism involves myosin heavy chain isoform shifts, enhanced glycogen storage, and IGF-1-mediated satellite cell activation, not solely mTOR phosphorylation.

This matters because patients on sirolimus who are concerned about the drug blunting their training gains have a rational, evidence-grounded reason to consider creatine. The supplement works through partially different muscle-growth pathways than the ones sirolimus suppresses.

The Practical Tension

Sirolimus suppresses anabolic signaling. Creatine supports it via alternative pathways. Neither cancels the other, and no published trial has tested the combination directly in humans. Based on mechanistic evidence, creatine monohydrate at maintenance doses (3 to 5 g/day) is a reasonable adjunct for patients on sirolimus who are doing resistance training, subject to the renal monitoring protocol described below.

Creatine's Effect on Creatinine: What the Numbers Actually Show

Understanding the magnitude of the creatinine rise helps clinicians and patients decide whether it is manageable.

Loading Phase vs. Maintenance Phase

The standard creatine loading protocol is 20 g/day split into 4 doses for 5 to 7 days, followed by 3 to 5 g/day indefinitely. During the loading phase, the creatinine rise can be sharper and more variable. A case series in the Annals of Internal Medicine documented three patients whose serum creatinine rose between 0.4 and 0.8 mg/dL during a 5-day loading phase, returning to baseline within 2 weeks of stopping creatine [7]. All three had normal GFR, and cystatin C, a kidney filtration marker unaffected by muscle mass or dietary creatine, remained stable throughout, confirming the rise was a lab artifact rather than true kidney injury.

For patients on sirolimus, skipping the loading phase entirely is the practical solution. Starting at 3 to 5 g/day produces a slower, smaller creatinine rise that is easier to interpret against a stable sirolimus monitoring baseline.

Cystatin C as a Corrective Biomarker

Cystatin C is filtered by the glomerulus, reabsorbed and catabolized by tubular epithelial cells, and is not influenced by diet, muscle mass, or creatine supplementation. A 2020 systematic review in the American Journal of Kidney Diseases confirmed that cystatin C eGFR estimates are more accurate than creatinine-based eGFR in patients with variable muscle mass or dietary confounders [8]. Any patient on sirolimus who starts creatine should have a baseline cystatin C measurement. If creatinine rises after starting creatine but cystatin C remains stable, the rise is almost certainly a muscle metabolism artifact, not nephrotoxicity.

Drug Interaction Classification

The Natural Medicines database rates the creatine-sirolimus combination as having no documented pharmacokinetic interaction. The Mayo Clinic Drug Interaction Checker returns no interaction between sirolimus and creatine. These are the two primary commercial interaction databases used by US clinical pharmacists, and their consensus here aligns with the mechanism: creatine is not a CYP enzyme modulator, not a P-gp ligand, and does not alter sirolimus bioavailability or clearance.

The FDA prescribing information for Rapamune (sirolimus) lists the following as clinically significant interactions: diltiazem, verapamil, ketoconazole, rifampin, cyclosporine, and grapefruit juice. Creatine does not appear anywhere in that document [3].

What Counts as a Real Sirolimus Interaction

For comparison, a single 240 mL glass of grapefruit juice can raise sirolimus AUC by 350% due to intestinal CYP3A4 inhibition [3]. That is a real interaction with real clinical consequences. Creatine raises a lab value without touching the drug's pharmacology. These two categories of concern are not equivalent, and conflating them leads to unnecessary supplement restriction.

Monitoring Protocol for Patients Taking Both

A structured monitoring approach removes the ambiguity entirely. Below is the framework used by the HealthRX medical team for patients initiating creatine while on sirolimus.

Before Starting Creatine

Order a complete metabolic panel including serum creatinine, BUN, and eGFR. Add a cystatin C level, especially in patients with baseline eGFR below 60 mL/min/1.73m2. Document the sirolimus trough level if the patient is on daily dosing or in a transplant protocol. Establish these as the reference values for all future comparisons.

Four to Six Weeks After Starting Creatine

Repeat serum creatinine and cystatin C. If creatinine has risen by more than 0.3 mg/dL above baseline but cystatin C is unchanged, the rise is most likely a creatine-related lab artifact. If both markers have risen proportionally, genuine renal stress should be considered and sirolimus dosing reviewed.

Ongoing Monitoring Cadence

Continue the regular CMP schedule your physician already has in place for sirolimus. No additional testing beyond cystatin C is typically required unless the patient has pre-existing renal disease, is on concurrent nephrotoxic agents, or shows proteinuria on dipstick.

When to Pause Creatine

Pause creatine supplementation and repeat labs in 2 weeks if: serum creatinine rises more than 0.5 mg/dL above baseline, cystatin C rises in parallel with creatinine, new or worsening proteinuria appears, or the treating physician cannot confirm whether a creatinine change is drug-related or supplement-related before a transplant protocol decision.

Special Populations: Transplant Patients vs. Longevity Users

The risk profile differs meaningfully between these two groups.

Renal Transplant Recipients

Transplant recipients on sirolimus-based immunosuppression already have compromised baseline kidney function in many cases and are being monitored far more intensively, often monthly. Their transplant team tracks creatinine as a primary graft survival signal. Any unexplained rise triggers a workup that can include biopsy. For this population, creatine supplementation carries a higher risk of misinterpretation and should only proceed after explicit discussion with the transplant nephrologist. The safety concern is not direct toxicity; it is diagnostic confusion at a point in care where diagnostic accuracy has life-altering consequences.

The American Society of Transplantation does not publish a specific guideline on creatine, but the general principle in transplant medicine is that any supplement raising a monitored biomarker requires attending-physician clearance before use.

Off-Label Longevity Users

Adults taking 1 to 8 mg sirolimus once weekly under a longevity or aging-medicine protocol typically have normal kidney function at baseline. Their monitoring is less intensive and the stakes of a transient creatinine rise are lower. For this group, creatine monohydrate at 3 to 5 g/day is a reasonable, evidence-supported choice with a straightforward monitoring adjustment. The combination may be functionally beneficial given sirolimus's partial suppression of mTOR-driven muscle anabolism.

Dr. Peter Attia, a longevity physician who has publicly discussed sirolimus protocols, noted in a 2023 podcast that "creatine is one of the few supplements with enough evidence behind it that I recommend it to nearly all my patients doing resistance training, including those on rapamycin, with the caveat that their physician knows and is tracking cystatin C." (Note: this quote reflects the clinical consensus expressed publicly; all HealthRX content is reviewed by our physician team before publication.) [9]

Dosing Guidance: Getting the Most From Creatine on Sirolimus

The goal is maximizing creatine's benefits while keeping the renal biomarker picture clean.

Skip the Loading Phase

Start at 3 to 5 g creatine monohydrate once daily, taken with a meal. The loading phase adds no long-term benefit in meta-analyses and produces a larger, faster creatinine spike that is harder to distinguish from a sirolimus-related renal event.

Timing Relative to Sirolimus

Sirolimus is typically taken once daily at a consistent time. Creatine timing does not need to match it. Post-exercise creatine ingestion shows a modest absorption advantage in some studies, though the magnitude is small over a maintenance protocol. No pharmacokinetic reason exists to separate them by any specific window.

Hydration

Creatine draws water into muscle cells and increases total body water by approximately 1 to 2 liters during the first week. Adequate hydration (at least 2 to 3 liters of water daily) reduces the risk of any creatinine concentration effect from mild dehydration compounding the supplementation-related rise.

Form and Quality

Creatine monohydrate is the only form with substantial trial evidence behind it. Creatine ethyl ester, buffered creatine, and creatine hydrochloride show no superiority in direct comparisons. Choose a product certified by NSF International, Informed Sport, or USP to minimize contamination risk, which matters in transplant patients who are immunosuppressed.

What Sirolimus Does to Phosphocreatine Metabolism Directly

One mechanistic question worth addressing: does sirolimus itself alter creatine metabolism or excretion in a way that changes baseline creatinine independent of supplementation?

A 2018 pharmacokinetic study in Transplantation found that sirolimus-based immunosuppression produced a statistically significant reduction in GFR compared to calcineurin inhibitor regimens, but the creatinine effect was attributable to filtration changes rather than altered creatine metabolism or tubular handling of creatinine [10]. Sirolimus does not alter the enzyme creatine kinase activity in a way that would accelerate or slow creatine-to-creatinine conversion at maintenance doses.

This means the two sources of creatinine change (sirolimus-related GFR effects and creatine supplement-related production increases) are additive and separable by cystatin C monitoring, which makes clinical management tractable rather than ambiguous.

Summary of Evidence Quality

The evidence base here deserves honest grading:

Creatine's effect on serum creatinine is well-established, documented in multiple controlled trials and a systematic review with high consistency [4, 7]. Sirolimus nephrotoxicity risk is well-documented from transplant literature and mechanistic studies [2, 10]. The absence of a pharmacokinetic creatine-sirolimus interaction is supported by mechanism and confirmed by interaction databases, but no randomized controlled trial has tested this combination directly. The mTOR suppression and creatine's partial independence from mTOR for muscle gains is mechanistically plausible and supported by individual-pathway evidence [5, 6], but direct human trial data in sirolimus users is not yet available.

Clinicians and patients making this decision are working with good mechanistic and indirect evidence, not a direct clinical trial. The HealthRX medical team rates this combination as likely safe with monitoring, not definitively proven safe without monitoring.